We wrote about ResMed (RMD) a few months ago in Livewire, warning of the downside

Michael Gable

Fairmont Equities

We wrote about ResMed (RMD) a few months ago in Livewire, warning of the downside. Patience has paid off for our readers and it has now become a buying opportunity. A quick summary of the fundamentals: 1. Leveraged to sleeping disorder volumes due to higher obesity rates in developed nations. 2. High product gross margins (> 60%). 3. Returns above the cost of capital (ROA > 15%). 4. Trading on a comparatively cheap multiple of 16.8x forward earnings. In terms of the charts, we have finally seen RMD break the shorter term downtrend last week. Now that it has been broken, it should resume the longer term uptrend, which implies levels up towards $6. Before then, we expect some strong resistance between $5.60 - $5.80.


1 topic

Michael Gable
Michael Gable
Managing Director
Fairmont Equities

Michael Gable is managing director of Fairmont Equities. We are a small boutique advisory that uniquely combines both fundamental and technical analysis. As a result, our analysis is featured regularly in the finance media such as the Australian...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment